{"id":"W4415734869","doi":"10.1182/bloodadvances.2025017745","title":"Decitabine-cedazuridine in patients with MDS and <i>TP53</i> mutations","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology; University of Texas MD Anderson Cancer Center; Genentech; Sierra Oncology; Daiichi Sankyo Europe; Gilead Sciences; Servier; Celldex Therapeutics; Daiichi-Sankyo; Pfizer; Incyte; CTI Biopharma; Agios Pharmaceuticals; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Celgene; BioCryst; Syndax Pharmaceuticals; Acceleron; Astex Pharmaceuticals; Ipsen; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Karyopharm Therapeutics; Ipsen Biopharmaceuticals; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma; Amgen","keywords":"Propensity score matching; Parenteral nutrition; Hypomethylating agent; Myelodysplastic syndromes; Cohort; Overall survival; Retrospective cohort study","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000778544,0.0001053225,0.0001968018,0.0002017424,0.0000522007,0.0000120698,0.0000618436,0.00003603944,0.00001598057],"category_scores_gemma":[0.0001533966,0.00007863783,0.0000155098,0.0005106147,0.0001045935,0.0001630651,0.00004487798,0.0001648176,0.000004983838],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000452186,"about_ca_system_score_gemma":0.0001567864,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002011855,"about_ca_topic_score_gemma":0.0000604415,"domain_scores_codex":[0.9991848,0.00002008292,0.000156421,0.0002314845,0.0001942794,0.0002128962],"domain_scores_gemma":[0.9995111,0.0001124957,0.00002868763,0.0001685816,0.0001073524,0.00007176262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003029337,0.0003333795,0.9863967,0.0001100687,0.00004962736,0.00003054375,0.00008004093,0.00002150176,0.0002957631,0.0004655014,0.0001962183,0.01171773],"study_design_scores_gemma":[0.01433295,0.0005975661,0.9644806,0.0003396339,0.0001347564,0.000009951262,0.0001880656,0.00006700565,0.004052226,0.0005377131,0.0150989,0.0001605901],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990599,0.001641903,0.00008210132,0.001059315,0.00003296483,0.0004140683,0.00001031854,0.00003333475,0.006126958],"genre_scores_gemma":[0.9953645,0.0002061751,0.003066232,0.0003617329,0.00002471364,0.0000470579,0.0000358361,0.000011542,0.0008822458],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02191605,"threshold_uncertainty_score":0.3206758,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.003920591795927492,"score_gpt":0.262517802524773,"score_spread":0.2585972107288455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}